Medical Marijuana Stock Plants First Seeds in $800M Brazilian Market

This is a paid advertisement from S3 Consortium Pty Ltd. HotCopper does not endorse, approve or have responsibility for the particular offer or statements made. [The Next Biotech]( [The Next Biotech]( [Medical Marijuana Stock Plants First Seeds in $800M Brazilian Market]( The ASX is buzzing with medical marijuana stocks right now. One $41M capped stock has been quick to set itself apart, with its focus on ‘quick to market’ nutraceutical products and a focus on the overlooked animal health market. Hot on the heels of news that its exclusive Australian market facilitator was granted a federal import license for cannabis products, this ASX company recently confirmed it is further extending its distribution footprint – this time on a global scale. This ASX stock has signed a commercial agreement in Brazil as part of its expansion into Latin America. The agreement is with a Brazilian distribution service company that already partners with global pharma brands such as Johnson & Johnson and GSK… and now our ASX listed company is there too. This company’s management team draws on decades of experience in both medical cannabis and the pharmaceutical industry – and this experience appears to be paying off. It will now work closely with its Latin American partner on the commercialisation of its premium Swiss Vitamin nutraceuticals and cannabinoid-derived nutraceutical products in Brazil. [WOULD YOU LIKE TO KNOW MORE?]( Sales of this company’s products in Brazil will target the privately insured middle class population of 60 million people. That is potentially a large addressable market $US800 million. This ASX stock expects first sales of its products in Brazil to occur in the second half of next year. Before that, two animal health products are expected to be launched in the coming months by the company in other regions. The information in this email should not be the only trigger for your investment decision. Click on the link below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions. Aside from Brazil, this company is, in fact, making inroads globally, after its acquisition of Slovakia-based Hemp-Industries which can provide early revenues, and opened up the East European market. At it builds a stronghold in Europe, Latin America and Australia, it may only be a matter of time before this ASX stock makes a significant contribution to the overall global medical cannabis market. [READ OUR FULL ARTICLE]( Regular readers of The Next Oil Rush, The Next Mining Boom, The Next Small Cap and The Next Tech Stock will know that we have a stellar track record of identifying high potential companies. PSC as high as 1,360%, VRC has been up as high as 1,150%, 88E has been up over 680%, EMH as high as 800%, and ICG as high as 525% since we first published articles on these stocks. SAS has been up as high as 870%, BLK has been as high as 600%, FBR has been as high as 530%, ADV as high as 410%, and NOX as high as 390%, since we published articles on these stocks. The past performance of The Next Oil Rush, The Next Mining Boom, The Next Small Cap, The Next Tech Stock, and The Next Biotech, is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. These products, like all other financial products, are subject to market forces and unpredictable events that may adversely affect future performance. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Longhou Capital Markets Pty Ltd (AFSL No. 292464). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. Conflict of Interest Notice S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article. [CUSTOMER NOTICE]( | [PRIVACY POLICY]( | [FINANCIAL SERVICES GUIDE]( | [DISCLOSURE POLICY]( Lvl 1, 530 Little Collins St, Melbourne, Victoria, 3000, AUSTRALIA [HotCopper]( [View this email online]( · [Unsubscribe]( · [Contact Us](mailto:info@hotcopper.com.au) You are receiving this email because you are a member of [HotCopper]( which is owned and operated by Report Card Pty Ltd. ABN: 39 092 598 859 ACN: 092 598 859. This is a paid advertisement. [Advertise on HotCopper](